(StatePoint) The bladder cancer treatment landscape is rapidly evolving, particularly for patients who don’t respond to bacillus Calmette–Guérin (BCG), the most common intravesical immunotherapy for early-stage bladder cancer.

However, as options expand, clinicians face added complexity in individualizing treatment paths, and in knowing what’s working. Fortunately, during evaluation and follow-up, they can lean on various enhanced diagnostic technologies, including approaches such as Blue Light Cystoscopy (BLC), to support timely adjustments in treatment.

Bladder-Sparing Therapies

Bladder-sparing therapies are offering new treatment avenues, potentially delaying or avoiding cystectomy for some patients. These therapies are aimed at managing the cancer while preventing the need to remove

See Full Page